Zydus Cadila gets USFDA nod for Anti Depressant drug

Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg Capsules - Indication of the drug is mood treatment

Medicine Capsule
Picture: Pixabay

Zydus Cadila has received final approval from the USFDA to market Nortriptyline Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg and 75 mg (US RLD: Pamelor Capsules).

This medication is used to treat mental / mood problems such as depression.

It may help improve mood and feelings of well-being, relieve anxiety and tension, and increase one’s energy level.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Also read:

Granules gets USFDA nod for Acetaminophen, Aspirin and Caffeine tablets

Strides gets USFDA Yes for Ibuprofen OTC Oral Suspension

Sun Pharma to launch entire range of Epilepsy treatment drug in India

Dr Reddy’s launch Lansoprazole DR orally disintegrating tablets

Unichem gets USFDA approval for Apremilast Tablets

Lupin gets USFDA nod to market generic Droxidopa capsules

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Go to main website, click here

Follow and connect with us on Facebook and Linkedin

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates